In SSc, the angiogenic process is severely impaired in the late phases of the disease [33], independent of the increased levels of circulating Vascular Endothelial Growth Factor (VEGF) and FGF2 [34,35]. The gene discussed is FGF2; the disease is systemic sclerosis.